Obermatt
See Similar Stocks →

Abeona Therapeutics

NAQ:ABEO · US00289Y2063
BiotechnologySmall

360

89
Profit price11
Owner Earnings Yield100
Dividend Yield1
Price/Sales68
Price/Book49
Return on Capital29
Cash Return on Capital100
Return on Equity100
Profit margins42
Accruals18
Owner Earnings Margin100
Sales growth100
Profit growth51
Reinvestment80
Price momentum30
Debt load50
Refinancing56
Debt Payback100
Liquidity16
Analyst ratings100
Opinion Changes50
Price Target Upside95
Market mood35
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Abeona Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees194
Websiteabeonatherapeutics.com
ISINUS00289Y2063
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Stem Cell TherapyOphthalmologyGeneticsPain ManagementGenetic DisorderBiomedical EngineeringCentral Nervous SystemBiotechnologyHealth CareManufacturingMedical Device

Description

Abeona Therapeutics Inc. (Abeona) is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (FDA) approved ZEVASKYN (prademagene zamikerac…

Analysis

Middle-of-the-road

Abeona Therapeutics Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 5.1× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is solid and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
84
2026

All-time high

84

Jun 2026

All-time low

84

Jun 2026

Average rank

84

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
68
—
—
—
Price/Earnings
92
—
—
—
Price/Book
49
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
94
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Abeona Therapeutics with its peers
ACADIA Pharmaceuticals
NSQ:ACAD
80
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ocular Therapeutix
NMQ:OCUL
21
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Fulcrum Therapeutics
NMQ:FULC
24
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Harmony Biosciences Holdings
NMQ:HRMY
94
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →